175 results
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
17 Apr 24
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
7:30am
-stage innovative therapies for critical conditions, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 … the resource intensive, late stage istaroxime program advanced by a larger company, by adding the innovative aPKCi inhibitor platform to our early
8-K
EX-99.1
q2zk3kyvsptjufolw1m6
15 Mar 22
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock
7:04am
8-K
EX-99.2
zle0fu
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
8-K
EX-99.1
bnvark
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
424B4
br8k6f5 a0hisdw0c
21 May 20
Prospectus supplement with pricing info
6:04am
8-K
EX-99.1
j2v6mc
14 May 20
Windtree Therapeutics Reports First Quarter 2020 Financial Results and Provides Key Business Updates
8:12am
8-K
EX-99.1
uk5 339auow83wz
29 Apr 20
Windtree Therapeutics Announces Reverse Stock Split
5:29pm
8-K
EX-99.1
1aw940
3 Apr 20
Windtree Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Key Business Updates
6:31am